The increased prices and low availability of medicines are main obstacles to health care system in developing countries like Bangladesh. The main goal of this work is to gather and assessing the data on availability, affordability and price variations of essential antibiotics in Bangladesh. The data will help to improve the availability and affordability of essential antibiotics for the mass peoples. The present work was done using standard methodology described in guideline, "Price measurement, availability and affordability and price components of medicines. A total of eighteen essential antibiotics were surveyed and their prices and availability were determined. Prices from 2003 to 2019 were collected from different sources to make a comparative study of the price variations over the years. The overall prices of essential antibiotics are not much higher than international reference prices. The rate of increase of price from previous years is not so alarming. The numbers of manufacturing companies were collected from the Bangladesh National Formulary (BDNF) of different Volumes to compare the increasing number of manufacturers. Essential antibiotics affordability was determined by comparing the total cost of treatment of a particular disease to the monthly salary of the lowest paid unskilled laborer. There are several essential antibiotics for which the numbers of manufacturing companies are increasing in very high rate. This type of survey may be expanded to the national level for the data of different regions of Bangladesh.
The insufficiency of access to essential antibiotics remains a great public health problem all over the world. World Health Organization (WHO) defines the essential medicines as "those medicines which meet the global health needs of the majority of the population of a particular territory". The WHO updates its Model Essential Medicines List every 2 years in a transparent way. Although access to essential medicines has improved since the introduction of the essential medicines concept in 1977, one-third of the world's population is still not treated with the required medicines that are needed for their treatment. In low-and middle-income countries (LMICs), as many as ninety percent of the population pay out-of-pocket for their drugs. The USA has also made a shift to high-deductible insurance strategy during within the last decades1.
In 2001, a resolution (WHA 54.11) endorsed by the Member States of the World Health Assembly called for a standardized procedure to monitor medicines prices to help boost the access. In response, the World Health Organization/Health Action International (WHO/HAI) Project on Medicine Prices and Availability was established. The primary purpose of this project was to develop a standardized method to calculate medicines' prices, availability, affordability and price components in a reproducible method so as to allow international comparisons against the time. In 2003, after testing in 9 countries, the standard WHO/HAI methodology was released, with a second edition published in 2008 2 .
Poor medicine availability, increased prices and low affordability are major obstacles to medicine access for common people in developing countries of the world. In many developed countries, for example, the USA, there are growing concerns about decreased medicine access for reasons including high medicine prices and copayments/deductibles, uninsured populations, inadequate transparency in medicine price components, and health agencies' low capability to bargain procurement prices 1 .
For the evaluation of the studied medicines' consumer prices, WHO/HAI methodology uses international reference prices (IRPs) as an external standard. To evaluate prices, a median price ratio (MPR) is measured by comparing the median consumer price of a supplied medicine with the particular IRP. International reference prices used in this work were taken from the 2015 Management Sciences for Health (MSH) International Drug Price Indicator Guide.
The MSH reference prices were published in 1986 for the first time. The MSH reference prices are procurement prices obtained from both sellers and purchasers and collected from government agencies, pharmaceutical suppliers and international development organizations. The MSH prices are widely accepted as proper reference standards 3. These MSH procurement prices report the real prices obtained by non-profit suppliers and government tenders, the robust nature of this data ensures international comparability 4 .
Government of any country should procure medicines from the reliable sources as compared to the IRPs patient prices from the private sector to reduce the excessive cost of the medicines occurring from the additional costs in markups, tariffs, taxes and other costs. Because of these additional costs, the WHO has set a target of 4 times the IRP for patient prices in the private sectors. Medicine availability and prices are recognized as an important components of access to medicines by WHO, For this reason the WHO five years strategic plan 2008-2013 defines the global and national targets for generic essential medicines, targeting 80% availability in all sectors and median consumer prices to be no more than four times the IRP. In studied works, the Median price ratios of studied medicines in Bangladesh varied from 0.36-2.56 and 0.33-2.36 in year 2015 and 2019, respectively.
Medicines included in this survey are used all over the world. The medicines are used to treat common conditions and appear on most treatment guidelines. Many of the surveyed medicines were studied in the 2009 study of medicine availability and prices in 36 developing and middle-income countries 3 .
In our work, we examined the availability of essential antibiotics across Model pharmacies and general retail stores. Prices were obtained from BDNF-2, BDNF-3, BDNF-4 and DGDA website of year 2003, 2006, 2015 and 2019, respectively, and essential antibiotics prices of 2015 according to BDNF 4 and 2019 according to DGDA website were then compared with the MSH IRPs. The current survey was performed using standard methodology stated in guideline Price measurement, availability and affordability and price components of medicines 2 .
The WHO/HAI Project on Medicine Prices and Availability was founded in 2001 -(i) to develop a effective methodology for accumulating and analyzing medicine price, availability, affordability and medicine price component data in different health-care sectors and regions in a country; (ii) to publish survey data on open access website to enhance price transparency; and (iii) to recommend for proper national policies and monitor their consequences.
The specific objectives of our study were -(i) to measure prices of Essential antibiotics for treating prevalent conditions in Bangladesh, (ii) to assess the affordability of standard treatment regimens utilizing these medicines, (iii) to compare the prices of drugs found in the country with international reference prices and (iv) to compare the prices of essential antibiotics of different years with statistical significance testing.
National drug policy 2016
Bangladesh Government has approved 3rd national drug policy of the country in its Cabinet Meeting that was held on 19 December 2016. To propose a draft of this policy, a drug policy formulation committee and sub-committee were constituted in 2011 5 . The sub-committee has analyzed meticulously the problems and prospects of the country's pharmaceutical sector, discussed with many professional experts and leaders of this sector, gathered opinion from all stakeholders and incorporated important suggestions from the public. Thus this drug policy has turned to be both pro-industry and pro-people.
Essential drug list (EDL)
To protect public health effectively and to deal with emergency need of the majority of the people, separate EDL for Allopathic, Ayurvedic, Unani and Homeopathic-Biochemic systems of medicines have been prepared. The quantity of drugs in the Essential Drug List (Allopathic) is 285 (versus 150 in the drug policy of 1982 with 56 in the Supplementary List), the number of medicines in the Essential Drug List (Ayurvedic) is 100, the quantity of drugs in the Essential Drug List (Unani) is 223 and the quantity of drugs in the Essential Drug List (Homeopathic) is 370.
All the drugs included in this list must be available throughout the country so that people even from remote corners can get an easy access to these drugs. After every 2 years, all these lists will be updated from time to time. Regular updating and inclusion of more drugs in this list will help us to get patent waiver of drugs on public health issue beyond 2033.
Regulatory system
The Directorate General of Drug Administration (DGDA), Ministry of Health and Family Welfare, is the National Regulatory Authority for drugs in Bangladesh. The DGDA oversees and implements all Drug laws in the country and guides all activities related to import, purchase of raw and packaging materials, manufacture and import of finished drugs, export, sales and price fixation, etc. Currently there are 28,734 brands of medicine products and a total of 269 drug manufacturing companies 6 . Year 2003
Year 2003
Year 2006
Year 
Methodology
With the help of the WHO/HAI methodology, we analyzed the availability, affordability and prices of 18 essential antibiotics. Availability of 18 essential medicines was obtained from 25 private pharmacies (Model pharmacies and general medicine stores). The medicine shops were located in different regions of the Dhaka Metropolitan City.
The prices of 18 essential medicines were also examined. The prices of drug were compared with international reference prices (IRPs). A comparative study on variation of prices across years was also done. A comparative statistical analysis among prices of different years was done by using SPSS statistic software. The local unit prices were collected from Bangladesh National Formulary which is the directory for all drugs produced locally and marketed in Bangladesh 7. International reference prices were utilized to compare national prices with the international standard.
The WHO/HAI methodology also evaluates the affordability of medicines, expressed as the number of day's salary needed by the lowest paid unskilled government laborer to buy a fullcourse of treatment. To estimate what drug prices mean in terms of affordability for mass people, some normal treatment costs were measured and compared with the salary of the lowest-paid unskilled laborer, which was 8000 Bangladeshi Taka per month8. All prices were converted to United States Dollar (USD) using the exchange rate on 30.06.2015 ($1 USD = 77.83 Bangladeshi Taka)9. The international prices of 2015 were used as reference unit prices.
Survey medicines
A total of 18 essential antibiotics were selected from the Essential drug list of Allopathic drugs published by Directorate General of Drug Administration. All essential antibiotics were dose and dosage-form specific. The surveyed essential antibiotics were shown in Table 1 . All surveyed essential antibiotics are generally used and have an available IRP. were then compared with the MSH 2015 IRPs. The drug prices were compared with international reference prices (IRPs). A comparative study on prices variation across years was also done. To ease international comparisons, medicine-specific median price ratios (MPR) were estimated when prices were available from at least four facilities.
The MPR refers to the ratio of a medicine's local median unit price as compared to the 2015 MSH international median unit reference price.
Availability of essential antibiotics
The availability of essential antibiotics was expressed in two ways. One was the national availability of medicines which was calculated by counting the number of manufacturer in the country. The manufacturer numbers were collected from Bangladesh National Formulary7, 10, 11, 12. Medicine availability was collected for different years as in 2001, 2003, 2006, 2015 and 2019 . The data for the year of 2019 were collected from DGDA website.
Our study investigated the availability of essential antibiotics across Model pharmacies and general retail stores. The availability of medicine in retail medicine shops was expressed as percentage to the number of sites on day of data collection. Only those medicines were considered available which were present at the time of data collection. Availability of 18 essential medicines were obtained from 25 private pharmacies (Model pharmacies and general medicine stores) and a comparison of mean percentage availability between 10 Model pharmacies and 15 General medicine stores were also studied using WHO/HAI methodology.
Affordability of essential antibiotics
The affordability of medicine was estimated as the number of days' wages that the lowest paid unskilled laborer would have to give for a standard treatment. As the government hospitals provide essential antibiotics to the patients free of cost, only the private sector medicine price was considered. The most common disease conditions were taken as standard for treatment approaches.
RESuLTS AND DiScuSSioN
The data for each medicine were collected from different sites and national formularies. Then the data were utilized in the program of MS Excel Workbook, given by the WHO/HAI. To avoid errors, data were checked and re-entered analysis among prices of different years was done by using SPSS statistical software.
Price of medicines
The prices of selected medicines (Shown in Table 1 ) of different years (2003, 2006, 2015 and 2019) were collected and listed (Shown in Table 2 ).The medicine unit prices gathered from the facility survey were placed into the MS Excelbased Workbook. A comparative statistical analysis among prices of different years was done by using SPSS statistical software (Shown in Table 3 ). There are some medicines of which prices changed dramatically. Sometimes prices increased and sometime remained almost the same. year 2019 was statistically significant (p value = 0.007).
comparison between year 2015 and 2019
Median prices of selected medicines increased in 2019 greatly compared to year 2015. This difference of prices between year 2015 and year 2019 was not statistically significant (p value = 0.510). Figure 2a showed that the Median unit price of Amoxicillin Capsule (250 mg A plot was drawn using selected antibiotics showed a great deviation in price over years ( Figure  3 
Median Price Ratio (MPR)
Median Price Ratio (MPR) of medicines was calculated to observe how many times greater or lesser the price of local medicines to international reference unit prices. The formula for calculating MPR is given below -Median Price Ratio (MPR) =(Median local unit price)/( Internationalreferenceunitprice)
The medicine prices of year 2015 and 2019 were converted to US Dollar using the exchange rate on 30.06.2015 ($1 USD = 77.83 Bangladeshi Taka) and 28.01.2019 ($1 USD= 83.4643 BDT), respectively. The international prices of 2015 were used as reference unit prices. Figure 4 showed that the Median Price Ratio (MPR) of Amoxicillin was 2.00 and 1.85 in 2015 and 2019, respectively; that of Ampicillin was 2.56 and 2.39 in 2015 and 2019, respectively; that of Phenoxymethyl Penicillin was 0.66 and 0.67 in 2015 and 2019, respectively; that of Benzathine Penicillin was 1.77 and 1.6 in 2015 and 2019, respectively; that of Flucloxacillin was 1.76 and 1.64 in 2015 and 2019, respectively; that of Procaine Penicillin was 0.61 and 0.4 in 2015 and 2019, respectively; that of Cephradine was not found; that of Cephalexin was 1.78 and 1.64 in 2015 and 2019, respectively; that of Benzyl Penicillin was 1. respectively; that of Cloxacillin was 1.32 and 1.25 in 2015 and 2019, respectively; that of Amoxiclav was 1.44 and 1.62 in 2015 and 2019, respectively; that of Erythromycin was 1.36 and 1.28 in 2015 and 2019, respectively; that of Chloramphenicol was 0.36 and 0.33 in 2015 and 2019, respectively; that of Doxycycline was 1.36 and 1.3 in 2015 and 2019, respectively; that of Co-Trimoxazole was 0.82 and 0.76 in 2015 and 2019, respectively; that of Metronidazole was 0.93 and 0.83 in 2015 and 2019, respectively; that of Tetracycline was 0.64 and 0.67 in 2015 and 2019, respectively; that of Nalidixic Acid was 1.44 and 1.1 in 2015 and 2019, respectively.
Availability of medicines
For assessing medicine availability, manufacturers of each medicine were counted. This gave the national availability of the medicines. By collecting data from different retail pharmacies, availability of medicines at regional level was determined. It is important to mention that the availability given in the results refers to all eighteen examined essential antibiotics. Only that antibiotics were seen at the time of data collection were termed as available. inspected to gather information about the described medicines. Availability of a medicine was ensured when one outlet had the medicine of any dose and dosage form on the time of data collection. However, data were collected from different types of retail pharmacies-large, small; medicine shop, model pharmacy; medicine stores located near the both government and non-government hospitals. The retail shops were located in different regions of the Dhaka Metropolitan City. In inspected retail shops, the essential antibiotics were poorly available in general medicine stores as compared to the Model pharmacies. So availability is higher in Model pharmacies than General medicine stores. Figure 6 showed that the availability of Amoxicillin was 100% and 93.3% in Model pharmacies and General medicine stores respectively; that of Ampicillin was 70% and 26% in Model pharmacies and General medicine stores respectively; that of Phenoxymethyl Penicillin was 90% and 53% in Model pharmacies and General medicine stores respectively; that of Benzathine Penicillin was 80% and 33.3% in Model pharmacies and General medicine stores respectively; that of Flucloxacillin was 100% and 86% in Model pharmacies and General medicine stores respectively; that of Procaine Penicillin was 20% and 0% in Model pharmacies and General medicine stores respectively; that of Cephradine was 100% and 80% in Model pharmacies and General medicine stores, respectively ; that of Cephalexin was 60% and 7% in Model pharmacies and General medicine stores, respectively; that of Benzyl Penicillin was 30% and 7% in Model pharmacies and General medicine stores, respectively; that of Cloxacillin was 90% and 26% in Model pharmacies and General medicine stores, respectively; that of Amoxiclav was 100% and 86% in Model pharmacies and General medicine stores, respectively; that of Erythromycin was 100% and 66% in Model pharmacies and General medicine stores respectively; that of Chloramphenicol was 70% and 40% in Model pharmacies and General medicine stores, respectively; that of Doxycycline was 90% and 66% in Model pharmacies and General medicine stores, respectively; that Fig. 7 . Affordability of essential antibiotics in Bangladesh of Co-Trimoxazole was 100% and 46% in Model pharmacies and General medicine stores respectively; that of Metronidazole was 100% and 86% in Model pharmacies and General medicine stores, respectively; that of Tetracycline was 100% and 46% in Model pharmacies and General medicine stores, respectively; that of Nalidixic Acid was 50% and 33.3% in Model pharmacies and General medicine stores, respectively.
Affordability of medicine
Medicine affordability was estimated by calculating the expenses of standard treatment to complete a full course (Shown in Table 7 ). The prices of medicines of 2019 were considered. The government of Bangladesh, on September 13, 2018 announced Tk. 8000 BDT as the minimum salary for Garment worker. The lowest monthly wage of unskilled people was considered as 8000 BDT . The economic condition of Bangladesh is also growing healthy. The per capita national income is also increasing every year. So the medicines are also becoming more affordable. The following table gives some idea about health and economic status of Bangladesh.
The number of day's salaries necessary to buy a course of treatment (shown in Table 8 ) was estimated from the daily wages of the lowest-paid unskilled laborer (266.67 BDT).
DiScuSSioN
In visited retail shops, the essential antibiotics were less available in general medicine stores as compared to the Model pharmacies. A comparative study on prices variation across years had shown a moderate increase in price. The median prices of surveyed antibiotics were obtained and a gross comparison was done that indicated % increase or decrease in price. In the study, the median price ratios of surveyed antibiotics ranged from 0.36-2.56 and 0.33-2.39 in Year 2015 and 2019, respectively. While observing the WHO target that patients should pay no more than four times the IRPs, we found that medicine prices were lower in the Bangladesh compared to IRPs. A medicine price survey in Bahrain during 2013 utilizing the WHO/HAI method, exhibited that patients were paying 34.78 and 13.85 times IRPs for innovator brands and lowest paid generics, respectively 1. Patients were paying 13.05 and 4.12 times IRPs for innovator brands and lowest paid generics, respectively during 2011 at Tatarstan Province of Russia. While patients were paying 61.44 and 17.33 times IRPs for innovator brands and lowest paid generics, respectively13, in a Caribbean country in 2010. Our findings gave the idea that the essential antibiotics were affordable in Bangladesh.
coNcLuSioNS

